Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Breast cancer treatment: perspectives on the oncolytic virus

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 21, 2024 5:13pm

151 Views

Post# 36234917

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virus

The first decade in immunotherapy started in 2014 when Merck beat Bristol Myers to market, gaining an accelerated approval in melanoma for pembrolizumab, or Keytruda, on Sept. 4, 2014, more than three months ahead of Opdivo.

While the two companies worked to shore up those first approvals in melanoma, a second prize awaited in a common form lung cancer.

Once again, Merck got there first, winning U.S. approval a week before Bristol Myers in October 2015 to treat people whose disease worsened following chemotherapy.

Over the course of the past decade, Merck and Bristol Myers also added approvals in numerous cancer types, including a “tissue agnostic” approval for Keytruda in people with a certain type of genetic mutation. These successes sparked a gold rush among other large pharma companies; First there was Roche with Tecentriq, and then followed drugs developed by Merck KGaA, AstraZeneca, Regeneron, GSK and others.

Still, PD1 drugs are not panaceas since approximately only 20-30% of the patients treated respond. What has been identified as a significant issue can be simply described as an immunosuppressed tumor microenvironment (TME) and insufficient level of TiLs and CD+8 cells that leads to T-cell exhaustion which are both critical for PD-L1 checkpoint inhibitors to become effective, and require to be reversed. ONCY's pelareorep has demonstrated that it is capable of remodeling the TME and stimulating the upregulation of TiLs and CD+8 cells in advance of PD-L1 administration, thus "priming" the immune system for the synergistic addition of a checkpoint inhibitor.

So now we are rolling into the second 10 year cycle of I/O drug develoment in which we are about to see another evolution, another 'step change' in I/O development, this time in combination with effective synergistic therapies. This time in combination with agents such as ONCY's pelareorep in the treatment of various orphan, rare, and cancers with unmet treatment needs.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record